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Abstract
Background: There is an immense clinical need for novel therapeutics for the treatment of angiogenesis-dependent
calcified neoplasms such as osteosarcomas and bone metastases. We developed a new therapeutic strategy to target bone
metastases and calcified neoplasms using combined polymer-bound angiogenesis inhibitors. Using an advanced ‘‘living
polymerization’’ technique, the reversible addition-fragmentation chain transfer (RAFT), we conjugated the aminobispho-
sphonate alendronate (ALN), and the potent anti-angiogenic agent TNP-470 with N-(2-hydroxypropyl)methacrylamide
(HPMA) copolymer through a Glycine-Glycine-Proline-Norleucine linker, cleaved by cathepsin K, a cysteine protease
overexpressed at resorption sites in bone tissues. In this approach, dual targeting is achieved. Passive accumulation is
possible due to the increase in molecular weight following polymer conjugation of the drugs, thus extravasating from the
tumor leaky vessels and not from normal healthy vessels. Active targeting to the calcified tissues is achieved by ALN’s
affinity to bone mineral.
Methods and Finding: The anti-angiogenic and antitumor potency of HPMA copolymer-ALN-TNP-470 conjugate was
evaluated both in vitro and in vivo. We show that free and conjugated ALN-TNP-470 have synergistic anti-angiogenic and
antitumor activity by inhibiting proliferation, migration and capillary-like tube formation of endothelial and human
osteosarcoma cells in vitro. Evaluation of anti-angiogenic, antitumor activity and body distribution of HPMA copolymer-ALN-
TNP-470 conjugate was performed on severe combined immunodeficiency (SCID) male mice inoculated with mCherry-
labeled MG-63-Ras human osteosarcoma and by modified Miles permeability assay. Our targeted bi-specific conjugate
reduced VEGF-induced vascular hyperpermeability by 92% and remarkably inhibited osteosarcoma growth in mice by 96%.
Conclusions: This is the first report to describe a new concept of a narrowly-dispersed combined polymer therapeutic
designed to target both tumor and endothelial compartments of bone metastases and calcified neoplasms at a single
administration. This new approach of co-delivery of two synergistic drugs may have clinical utility as a potential therapy for
angiogenesis-dependent cancers such as osteosarcoma and bone metastases.
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Introduction
There is an unmet medical need for new targeted treatments for
bone neoplasms such as bone metastases and osteosarcoma.
Approximately 60%–84% of patients diagnosed with solid tumors
develop bone metastases. Prostate, breast, lung, kidney, and
thyroid cancers account for 80% of skeletal metastases [1]. Out of
the bone neoplasms, osteosarcoma, is the most common type of
primary bone cancer and classified as a malignant mesenchymal
neoplasm in which the tumor directly produces impaired osteoid
[2]. It is a highly vascular and extremely destructive malignancy
that most commonly arises in the metaphyseal ends of long bones
[3]. Over the past two decades, multimodality treatment consisting
of aggressive chemotherapy combined with radical surgical
resection, has been the mainstay of osteosarcoma management,
with achievable 5 year survival rates of 50 to 70% in patients who
do not have metastatic disease at presentation. Several strategies
were proposed [4], however, still one-third of the patients die from
this devastating cancer, and for those with unresectable disease
there are no curative systemic therapies.
Tumor progression and metastases are highly dependent on
oxygen and nutrients supplied by new angiogenic blood vessels
which formation is stimulated by the tumor itself and its
environment [5]. Anti-angiogenic therapy combined with con-
ventional treatment holds great potential for osteosarcoma
management and metastatic risk reduction. There is a vast
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angiogenics are effective treatments for osteosarcomas [4,6,7] and
for bone metastases originating from prostate and breast cancers
[8,9,10]. Several angiogenesis inhibitors have been recently
approved for clinical use [11,12]. Angiogenesis inhibitors, such
as TNP-470 [13] and its non-toxic N-(2-hydroxypropyl)methacry-
lamide (HPMA) copolymer-conjugated form, caplostatin [13,14],
are emerging as a new modality of anticancer drugs. Nonetheless,
synthesizing new targeted angiogenesis inhibitors, optimizing their
dose and determining the best combinations of novel angiogenesis
inhibitors remain formidable challenges. These hurdles may limit
the use of a single anti-angiogenic agent. Another noteworthy
obstacle is that the vast majority of clinically used anticancer and
anti-angiogenic drugs are small molecules that exhibit a short half-
life in the bloodstream and a high overall clearance rate. These
low-molecular weight drugs diffuse rapidly into healthy tissues and
are distributed evenly within the body. As a consequence,
relatively small amounts of the drug reach the target site, and
therapy is associated with low efficacy and severe side effects
[15,16].
Here we describe the synthesis and characterization of a novel
conjugate of HPMA copolymer, TNP-470 and the aminobispho-
sphonate, alendronate (ALN). TNP-470 is a low molecular weight
synthetic analogue of fumagillin able to selectively inhibit
angiogenesis and suppress tumor growth [17]. In clinical trials, it
slowed tumor growth in patients with metastatic cancer. However,
at higher doses necessary for tumor regression, many patients
experienced toxicity [18]. Because of dose limiting neurotoxicity,
TNP-470 has been stalled in Phase II. Due to its strong potency,
poor pharmacokinetic profile, and poor solubility, TNP-470 is an
ideal candidate for polymer conjugation. Thus, to apply this drug
clinically to more effectively treat tumors, drug targeting to tumor
tissue is necessary to increase site specificity and reduce side effects.
We have recently shown that caplostatin, an HPMA copolymer
conjugate of TNP-470 prolonged the circulating life of the drug,
increased the accumulation of the drug in angiogenic tissue
through the enhanced permeability and retention (EPR) effect [19]
and prevented it from crossing the blood brain barrier (BBB),
therefore abrogating neurotoxicity [13,20,21]. Several other TNP-
470 analogs [22,23,24] or alternatively Methionine-aminopepti-
dase-2 (MetAP2) inhibitors [25,26,27,28] have been recently
developed with the aim of ‘‘resurrecting’’ TNP-470 [29].
Bisphosphonates (BPs) are analogues of inorganic pyrophos-
phate, an endogenous regulator of bone mineralization [30,31].
Several BPs are effective treatments in osteoporosis, Paget’s disease
of bone, myeloma, and bone metastases [32]. BPs have been
shown to inhibit angiogenesis [33,34]. Furthermore, there is a vast
amount of literature on the use of BPs for the treatment of bone
metastases originating from prostate and breast cancers
[9,35,36,37,38]. Their strong affinity to bone mineral [39], their
low toxicity and anti-angiogenic activity make the BPs excellent
candidates for targeting calcified neoplasms. There are several
studies and publications describing the conjugation of BPs directly
to cancer treating agents like antineoplastics, radionucleotides or
nucleoside analogs for the treatment of bone metastases [40]. ALN
is a nitrogen-containing BP drug approved by the FDA that acts as
a specific inhibitor of osteoclast-mediated bone resorption and
several other bone diseases [41,42]. ALN is considered one of the
potent BP for the treatment of bone related diseases and cancer-
associated hypercalcemia. It was shown to have antitumor effect in
several in vivo cancer models through several different mecha-
nisms [43,44,45]. In addition, ALN was found to have anti-
angiogenic activity through (i) suppression of VEGF-induced Rho
activation in an ovarian cancer model [46], (ii) inhibition of a key
enzyme, farnesyl pyrophosphate synthase, in the mevalonate
pathway, thereby preventing the biosynthesis of isoprenoid
compounds that are essential for the posttranslational modification
of small guanosine triphosphate (GTP)-binding proteins such as
Rab, Rho, and Rac [47]; and (iii) regulation of cellular level of
MMP-2 expression in osteosarcoma cell lines [48]. ALN bears a
primary amine which facilitates conjugation with HPMA copol-
ymer through a cathepsin K-cleavable linker, glycine-glycine-
proline-norleucine (Gly-Gly-Pro-Nle). Cathepsin K is involved in
bone resorption and its expression is stimulated by inflammatory
cytokines that are released after tissue injury and in bone
neoplasms [12,49]. We propose that combined therapy of an
HPMA copolymer-ALN-TNP-470 conjugate, can be used as a
preventive or curative new concept of anti-angiogenic and
antitumor treatment. A major benefit of polymer-targeted
angiogenesis inhibitors is reduced toxicity compared to conven-
tional cytotoxic agents [50]. Consequently, beside their use in
clinically evident disease, our targeted polymer therapeutics may
potentially be used for the treatment of asymptomatic individuals
who are at risk for relapse of ostesarcoma, breast and prostate
cancer metastases. This approach may lead to a major paradigm
shift in cancer treatment from current methods where treatment is
generally not initiated until the cancer becomes clinically evident
[13].
Materials and Methods
Materials
Cathepsin K inhibitor III was purchased from Calbiochem,
Germany. Phalloidin-TRITC conjugate, Propidium iodide (PI)
and hydroxyapatite (HA) were purchased from Sigma-Aldrich,
Israel. ALN was from Alcon Biosciences, India. Ultra pure double
distilled water (DDW) was purchased from Biological Industries,
Israel. AntifadeH mounting medium was from Biomeda Corp.
AlexaH Fluor 594 human transferrin was from Molecular
Probes
TM. Peroxidase Block was purchase from Merck, Germany.
Primary rat anti-murine CD34 antibody (MEC 14.7) was from
Abcam, (Cambridge, MA). Rabbit anti-rat antibody, anti-rabbit
horseradish peroxidase-conjugated antibody (ABC detection kit)
and ImmPACT
TM DAB diluent kit were from Vector Laborato-
ries, CA, USA. Boyden chambers 8 mm were from Transwell-
Costar Corp. Hema 3 Stain System was from Fisher Diagnostics.
EGM-2 medium was from Cambrex, USA and endothelial cells
growth supplement (ECGS) from Zotal, Israel. All other chemical
reagents, including salts and solvents, were purchased from Sigma-
Aldrich. All reactions requiring anhydrous conditions were
performed under an Ar or N2 atmosphere. Chemicals and
solvents were either A.R. grade or purified by standard techniques.
Cell culture
Saos-2 and MG-63-Ras human osteosarcoma cells were
obtained from the American Type Culture Collection (ATCC).
MG-63-Ras cells were transfected with activated ras (MG-63-Ras)
as previously described in order to generate an in vivo fast-growing
tumor cell line [51]. Cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 100 mg/ml Penicillin, 100 U/ml Streptomycin,
12.5 U/ml Nystatin and 2 mM L-glutamin (Biological Industries,
Israel). Cells were grown at 37uCi n5 %C O 2. mCherry-labeled
MG-63-Ras human osteosarcoma cell line was obtained by
infection with a pQC-mCherry retroviral vector. The infected
cells were selected for stable expression of mCherry using
puromycin. Human umbilical vein endothelial cells (HUVEC)
were purchased from Lonza, Switzerland. HUVEC were cultured
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5% CO2.
Methods
Ethics Statement. All animal procedures were performed in
compliance with Tel Aviv University, Sackler School of Medicine
guidelines and protocols approved by the Institutional Animal
Care and Use Committee. Mice’s body weight and tumor size
were measured three times a week.
Generation of mCherry-infected MG-63-Ras human
osteosarcoma cell line
mCherry was subcloned from pART7-mCherry (kindly provid-
ed by A. Avni from Tel Aviv University), into pQCXIP (Clontech).
Human embryonic kidney 293T (HEK 293T) cells were co-
transfected with pQC-mCherry and the compatible packaging
plasmids (pMD.G.VSVG and pGag-pol.gpt). Forty eight hours
following transfection, the pQC-mCherry retroviral particles
containing supernatant was collected. MG-63-Ras human osteo-
sarcoma cells were infected with the retroviral particles media, and
48 h following the infection, mCherry positive cells were selected
by puromycin resistance.
Cell proliferation assay
HUVEC were plated at 10,000 cells/well onto 24-well culture
plates in EBM-2 supplemented with 5% FBS and incubated for
24 h (37uC; 5% CO2). Medium was replaced with 2.5% EBM-2
supplemented with 1% ECGS. Human osteosarcoma Saos-2 or
MG-63-Ras cells were plated at 2500 cells/well in DMEM
supplemented with 5% FBS and incubated for 24 h (37uC; 5%
CO2). The medium was then replaced with DMEM supplemented
with 10% FBS. Cells were exposed to ALN, TNP-470, and HPMA
copolymer-ALN-TNP-470 conjugate or with equivalent concen-
trations of combinations of free ALN and TNP-470 at serial
dilutions. HUVEC were incubated with or without 1 mMo f
cathepsin-K inhibitor III. Control cells were grown in the presence
or absence of growth factors. HUVEC or Saos-2 viable cells were
counted by a Z1 CoulterH Particle Counter (Beckman Coulter
TM)
or by XTT reagent respectively after 72 h of incubation.
Isobolograms of ALN-TNP-470 drug combination
treatments
IC50 represents the concentration of a drug that is required for
50% inhibition in vitro. The IC30, 50, 70 values of treatment with
ALN, TNP-470 and their respective combinations were calculated
from HUVEC proliferation assay. IC30, 50, 70 values of TNP-470
and ALN were marked on X, Y axis respectively and a line which
represents additive effect was drawn between each inhibitory
concentration (IC). The combination index of each treatment was
calculated according to the classic isobologram equation combi-
nation index=[(D)1/(Dx)1]+[(D)2/(Dx)2] as previously described
[52]. Area on the right side of each IC additive line represents
antagonist effect while the left side represents synergic effect.
Synthesis of HPMA copolymer-ALN-TNP-470 conjugate
Synthesis of ALN containing monomer (MA-Gly-Gly-Pro-
Nle-ALN). The monomer was synthesized as described
previously [27]. Briefly, MA-Gly-Gly-Pro-Nle was synthesized by
solid phase peptide synthesis (SPPS) and manual Fmoc/tBu
strategy using 2 g of 2-chlorotrityl chloride beads with 80% of
loading leading to a yield of 0.88 g, 95%. MA-Gly-Gly-Pro-Nle-
OH (100 mg, 0.24 mmol) and 2-mercaptothiazoline (TT, 33 mg,
0.28 mmol) were dissolved in a mixture of 2 ml 1,4-dioxane and
1 ml tetrahydrofuran (THF), and cooled to 4uC. DCC (60 mg,
0.29 mmol) in 1 ml of 1,4-dioxane was added dropwise and the
reaction mixture stirred overnight at 4uC. After the reaction, DCU
was removed by filtration andthefiltratewasaddedtoALNaqueous
solution (70 mg, 4 ml; pH was adjusted to ,7.4 by NaHCO3
solution). The reaction mixture was stirred overnight at room
temperature. The solvent was removed on a rotary evaporator, the
residue was re-dissolved in water and extracted with ethyl acetate 3
times to remove TT. The product was purified by preparative high
performance liquid chromatography (HPLC) with a yield of 83 mg.
The MALDI-TOF spectrum negative ion: m/z=640 (M2H
+), 662
(M-mono-Na salt2H
+); positive ion: m/z=642 (M+H
+), 664 (M-
mono-Na salt+H
+), 686 (M-mono-Na salt+Na
+).
Synthesis of amine containing monomer (MA-Gly-Gly-
Pro-Nle-NH(CH2)2NH2). MA-Gly-Gly-Pro-Nle-
NH(CH2)2NH2 was synthesized by SPPS using 1.5 g of 2-
chlorotrityl chloride beads. First, 6 times excess of
ethylenediamine in anhydrous THF was applied, followed by
Fmoc-amino acids, and capping with MA-Gly-Gly-OH. The final
peptide was cleaved by 5% TFA in dichloromethane (DCM) with
a yield of 0.85 g, 89%. The purity of product was proved by
HPLC (buffer A: H2O 0.1% TFA, buffer B: acetonitrile
0.1%TFA; gradient method: buffer B 2%–60%/30 min; 1 ml/
min; single peak, elution time 8.27 min). The MALDI-TOF
spectrum (Fmoc derivative) positive ion: m/z=697 (M+Na
+), 713
(M+K
+).
Synthesis FITC containing monomer (MA-FITC).
Fluoresceinisothiocyanate (FITC) (1 g, 2.57 mmol) and N-(3-
aminopropyl) methacrylamide hydrochloride (0.92 g, 5.14 mmol)
were dissolved in 5 ml dimethylformamide (DMF) and cooled to
4uC, then N,N-diisopropylethylamine (DIPEA) (1.79 ml,
10.3 mmol) in 2 ml of DMF was added dropwise. The reaction
mixture was stirred at 4uC for 2 days. Then, the reaction mixture
was poured into 100 ml water (pH,4–5) and pH adjusted to ,4
by 6 N HCl. The precipitate was filtered off, washed with water,
and vacuum dried over P2O5.
Synthesis of polymer precursor containing ALN, NH2,
and (optionally) FITC groups (HPMA copolymer-ALN-
NH2). MA-Gly-Gly-Pro-Nle-ALN (73 mg), MA-Gly-Gly-Pro-
Nle-NH(CH2)2NH2 (55 mg), HPMA (200 mg), MA-FITC (0 mg
or 4 mg) and 4,49-azobis(4-cyanovaleric acid) (V-501, 3 mg) as the
initiator were dissolved in 2 ml of water. The solution was bubbled
with N2(g) for 10 min, the ampoule sealed, and the mixture
polymerized at 60uC for 24 h.
Alternatively, we used reversible addition-fragmentation chain
transfer (RAFT) polymerization technique. MA-Gly-Gly-Pro-Nle-
ALN (293 mg), MA-Gly-Gly-Pro-Nle-NH(CH2)2NH2 (215 mg),
HPMA (948 mg), MA-FITC (0 mg or 4 mg), 2,29-Azobis[2-(2-
imidazolin-2-yl)propane]dihydrochloride (VA-044 1.6 mg) as ini-
tiator and S,S9-bis(a,a9-dimethyl-a0-acetic acid) trithiocarbonate as
chain transfer agent (TTC 4.2 mg) were dissolved in 7.5 ml of
water. The solution was bubbled with N2(g) for 30 min, sealed in
ampoule , and the mixture polymerized at 30uC for 48 h. Both
resulting polymers were purified by dissolving in water and
precipitating into an excess of acetone; following each precipita-
tion, the precipitate was washed with acetone. Finally, the
polymers were dissolved in 15 ml of water; pH adjusted to 12
with 1 N NaOH, and dialyzed against DI water for 24 h at 4uC
(MWCO 12-14 kDa) to remove ALN monomer. The samples
were freeze-dried after dialysis.
Binding of TNP-470 to HPMA copolymer-ALN. HPMA
copolymer-ALN-NH2 (150 mg) was dissolved in 6 ml of DMF (if
necessary, a small amount of water was added to dissolve the
polymer) and cooled to 4uC. Then, TNP-470 (150 mg) in 1 ml
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for 12 h. Following the reaction, the conjugate was precipitated
into acetone and purified by reprecipitation (3 times) from an
aqueous solution into an excess of acetone. The precipitate was
washed with acetone and the residue was dissolved in water and
dialyzed for 1 day at 4uC (MWCO 12–14 kDa) against DI water.
The conjugate was isolated by freeze-drying.
Characterization of HPMA copolymer-ALN-TNP-470
conjugate (Scheme S1)
Determination of ALN content. The formation of
chromophoric complex between ALN and Fe
3+ ions in
perchloric acid solution was used to determine the ALN content
by spectrophotometry [53]. Briefly, 0.1 ml conjugate (conc. 2–
10 mg/ml) was mixed with 0.1 ml 4 mM FeCl3 and 0.8 ml 0.2 M
HClO4 and absorbance at 300 nm was measured against blank.
The calibration curve was prepared by using ALN solution at
concentration range 0–3 mM.
Estimation of TNP-470 content
The content of TNP-470 was estimated from the content of
NH2 groups in the HPMA copolymer-ALN-NH2 precursor
(Scheme S1). It was assumed that the TNP-470 binding was
quantitatively equal. The content of NH2 groups was determined
by ninhydrin method using an amine containing monomer (N-(3-
aminopropyl) methacrylamide) as the calibration sample [modified
from [45]].
Determination of FITC content
The content of FITC was measured spectrophotometrically
using e 80000 M- 1 cm-1 in 0.1 M borate buffer (Scheme S1).
Determination of HPMA copolymer-ALN-TNP-470
conjugate molecular weight and polydispersity index (PDI)
Determination of polymer-drug molecular weight profile by size
exclusion chromatography (SEC) was done using AKTA/FPLC
system (Pharmacia/GE Healthcare), Superose 12 HR10/30 column
in 0.1 M acetate buffer pH 5.5+30% acetonitrile, pH 5.5, flow rate
0.4 ml/min;UVand RIdetection. Weight averagemolar mass(Mw)
was evaluated from the SEC profiles and the PDI was calculated
according to the formula Mw/Mn. The column was calibrated using
polyHPMA fractions of narrow polydispersity.
Quantitative evaluation of HPMA copolymer-ALN-TNP-
470 conjugate size distribution
The mean hydrodynamic diameter of the conjugate was
evaluated using a real time particle analyzer (NanoSight LM20
TM)
containing a solid-state, single mode laser diode (,20 mW,
655 nm) configured to launch a finely focused beam through a
500 ml sample chamber. HPMA copolymer-ALN-TNP-470 con-
jugate was dissolved in phosphate buffered saline (PBS) to final
concentrations of 0.5, 1 and 2 mg/ml. The samples were then
injected into the chamber by syringe and allowed to equilibrate to
unit temperature (23uC) for 30 sec. The particles dynamics were
visualized at 30 frames per second (fps) for 60 sec at 6406480
resolution by the coupled charge device (CCD) camera. The paths
the particles take under Brownian motion over time were analyzed
using Nanoparticle Tracking Analysis (NTAH) software. The
diffusion coefficient and hence sphere equivalent hydrodynamic
diameter of each particle was separately determined and the
particle size distribution profiles were generated. Each sample was
measured three times in triplicates, and the results represent the
mean diameter.
Hydroxyapatite (HA) binding assay
In order to assess the ability of HPMA copolymer-ALN-TNP-
470 conjugate to bind to bone mineral its binding potency to HA
was evaluated. HPMA copolymer-ALN-TNP-470 conjugate was
dissolved in PBS, pH 7.4 (1 mg/ml). The conjugate solution
(500 ml) was incubated with HA powder (15 mg), in 500 ml PBS,
pH 7.4. HPMA copolymer-Gly-Phe-Leu-Gly was used as control.
Incubated samples were centrifuged at 6000 RPM for 3 min and a
sample from the upper layer (100 ml) was collected at selected time
points. FPLC analysis using HiTrap desalting column (Amer-
shamH) was used for detection of unbound conjugate in the
samples (FPLC conditions: AKTA
TM PurifierH, mobile phase
100% DDW, 2 ml/min, 215 nm). HA-binding kinetic analysis of
the conjugate was performed using the UnicornH AKTA
TM
software. Areas under the curve (AUC) were calculated from
chromatographs at each time point. AUC of each HA-incubated
conjugate chromatogram was normalized to percent AUC of
conjugate sample in the absence of HA used as control.
Intracellular trafficking of HPMA copolymer-ALN-TNP-470
conjugate
For all experiments, HUVEC and Saos-2 human osteosarcoma
cells were seeded on sterile 13 mm cover glasses in 35 mm culture
dishes 24 h before incubation with FITC-labeled HPMA copol-
ymer-ALN-TNP-470 conjugate. HUVEC and Saos-2 cells were
incubated with 10 mM HPMA copolymer-ALN-TNP-470 conju-
gate for 12 h, then washed several times with cold PBS, fixed with
3.5% paraformaldehyde for 15 min at room temperature (RT)
and washed with PBS again. For counter staining, cells were
permeabilized with 0.1% Triton-X100 for 3 min and rinsed with
PBS again. For confocal imaging of FITC-labeled HPMA
copolymer-ALN-TNP-470 conjugate cellular uptake by HUVEC,
nuclei were labeled using propidium iodide (10 mg/ml) and cover
glasses were mounted by AntifadeH mounting media. Alternative-
ly, actin filaments were labeled using phalloidin-TRITC conjugate
(50 mg/ml, 40 min at RT) and cover glasses were mounted by
VectashildH DAPI containing medium. For conjugate endosomal
pathway internalization analysis, HUVEC and Saos-2 cells were
incubated with 10 mM HPMA copolymer-ALN-TNP-470 conju-
gate for 6 h. Following incubation, cells were washed several times
with cold PBS, starved for 45 min in serum-free medium at 37uC
and incubated with 40 mg/ml AlexaH Fluor 594 human transferrin
for 1 h at 37uC. Cells were then fixed and mounted as described
before. All slides were kept at 4uC in dark until confocal
microscopy analysis was preformed.
Confocal microscopy
Cellular uptake, internalization and colocalization of FITC-
labeled HPMA copolymer-ALN-TNP-470-FITC conjugate were
monitored utilizing a Zeiss Meta LSM 510 and a Leica TCS SP5
confocal imaging systems with 606oil objectives. All images were
taken using a multi-track channel acquisition to prevent emission
cross-talk between fluorescent dyes. Single XY, XZ plane-images
were acquired in 102461024 resolution. Images from Z stack
acquisition were processed as separate channels using HuygensH
deconvolution software and merged as a single image.
HUVEC migration assay
Cell migration assays were performed using modified 8 mm
Boyden chambers coated with 10 mg/ml fibronectin. HUVEC
(15610
4 cells/100 ml) were exposed to HPMA copolymer-ALN-
TNP-470 conjugate or to combinations of free ALN and TNP-470
at equivalent concentration and were added to the upper chamber
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migrate to the underside of the chamber for another 4 h in the
presence or absence of vascular endothelial growth factor (VEGF)
(20 ng/ml) in the lower chamber. Cells were then fixed with ice-
cold methanol and stained (Hema 3 Stain System). The stained
migrated cells were imaged using Nikon TE2000E inverted
microscope integrated with Nikon DS5 cooled CCD camera by
106 objective, brightfield illumination. Migrated cells from the
captured images per membrane were counted using NIH image
software. Migration was normalized to percent migration, with
100% representing migration to VEGF alone.
Capillary-like tube formation assay
The surface of 24-well plates was coated with MatrigelH
basement membrane (50 ml/well; 10 mg/ml) on ice and was
allowed to polymerize at 37uC for 30 min. HUVEC (3610
4 cells)
were exposed to HPMA copolymer-ALN-TNP-470 conjugate or
with combinations of free ALN and TNP-470 at equivalent
concentrations and were seeded on coated plates in the presence of
complete EGM-2 medium. Following 8 h of incubation (37uC; 5%
CO2), cells were imaged using Nikon TE2000E inverted
microscope integrated with Nikon DS5 cooled CCD camera by
46 objective, brightfield illumination. Images were analyzed for
total tube area using Nikon NISH elements image software.
Miles vascular permeability assay
Balb/c male mice were injected subcutaneously (s.c.) with TNP-
470, HPMA copolymer-ALN-TNP-470 conjugate (30 mg/kg
TNP-470 equivalents) or saline (n=5 mice/group). Three days
later, a modified Miles assay was performed as previously
described [54,55]. Briefly, Evans blue dye (100 ml of a 1% solution
in 0.9% NaCl) was injected into the retro-orbital plexus of the
mice. Ten minutes later, 50 ml of human VEGF165 (1 ng/ml) or
PBS were injected intradermally into the pre-shaved back skin.
Twenty minutes later, the animals were killed, and an area of skin
that included the entire injection site was removed. Evans blue dye
was extracted from the skin by incubation with formamide for 5
days at room temperature, and the absorbance of the extracted
dye was measured at 620 nm. Data is expressed as mean6-
standard error of the mean (s.e.m.).
Evaluation of antitumor activity of HPMA copolymer-
ALN-TNP-470 conjugate
SCID male were inoculated s.c. with 5610
5 mCherry-labeled
MG-63-Ras human osteosarcoma. Mice bearing 70 mm
3 tumors
were injected s.c. with combination of free ALN and TNP-470
(1:1, 30 mg/kg), FITC-labeled HPMA copolymer-ALN-TNP-470
conjugate (30 mg/kg q.o.d.63 times TNP-470-equivalent dose) or
saline (n=5 mice/group). Therapy was initiated at a relatively
early state (70 mm
3) in order to imitate a metastatic scenario as
well as an early primary osteosarcoma. Tumor progression was
monitored by caliper measurement (width6length
260.52) and by
CRI
TM Maestro non-invasive intravital imaging system. At
termination, tumors were dissected, weighed and analyzed. Data
is expressed as mean6standard error of the mean (s.e.m.).
Intravital non-invasive imaging of mCherry-labeled MG-
63-Ras tumor-bearing mice and FITC-labeled HPMA
copolymer-ALN-TNP-470 conjugate biodistribution in
mice
CRI Maestro
TM non-invasive fluorescence imaging system was
used to follow tumor progression of mice bearing mCherry-labeled
MG-63-Ras human osteosarcoma tumors and for biodistribution
studies of FITC-labeled HPMA copolymer-ALN-TNP-470 con-
jugate. Mice were maintained on a non-fluorescent diet (Harlan)
for the whole period of the experiment. Mice were anesthetized
using ketamine (100 mg/kg) and xylazine (12 mg/kg), treated with
a depilatory cream (VeetH) and placed inside the imaging system.
Alternatively, selected organs from mice were dissected and placed
inside the imaging system. Multispectral image-cubes were
acquired through 550–800 nm spectral range in 10 nm steps
using excitation (575–605 nm) and emission (645 nm longpass)
filter set. Mice autofluorescence and undesired background signals
were eliminated by spectral analysis and linear unmixing
algorithm. Additionally, dissected tumors were fixed in 4% PFA
and imaged as whole-mount by confocal microscopy as described
earlier in order to assess the conjugate accumulation in the tumor
site.
Immunohistochemistry
Immunohistochemistry of tumor nodules was performed using
5 mm thick formalin-fixed, paraffin-embedded tissue sections.
Paraffin sections were de-paraffinized, rehydrated, and stained
by hematoxylin and eosin (H & E). For CD34 staining, slides were
deparaffinized and pre-treated with 10 mM citrate, pH 6.0 for
50 min in a steam pressure cooker (Decloaking Chamber, BioCare
Medical, Walnut Creek, CA). All further steps were performed at
RT in a hydrated chamber. Slides were covered with Peroxidase
Block (Merck, Germany) for 5 min to quench endogenous
peroxidase activity, followed by incubation with 10% of rabbit
serum in 50 mM Tris-HCl, pH 7.4, for 30 min to block non-
specific binding sites. Primary rat anti-murine CD34 antibody
(MEC 14.7 1:50 dilution; Abcam, Cambridge, MA) was applied in
1% rabbit serum in Tris-HCl, pH 7.4 at RT for 1 h. Slides were
washed in 50 mM TrisHCl, pH 7.4 and rabbit anti-rat antibody
(1:750 dilution; Vector Laboratories, CA, USA) was applied for
30 min, followed by anti-rabbit horseradish peroxidase-conjugated
antibody (ABC detection kit, Vector Laboratories, CA, USA).
Following further washing, immunoperoxidase staining was
developed using a ImmPACT
TM DAB diluent kit (Vector
Laboratories, CA, USA) per the manufacturer instructions and
counterstained with methyl green. Microvessel density (MVD) was
calculated as previously described [56].
Statistical methods
In vitro data from proliferation assays on HUVEC, MG-63-Ras
and Saso-2 cells, HUVEC’s migration and capillary-like tube
formation expressed as mean6standard deviation (s.d.). In vivo
data of Miles assay and evaluation of antitumor activity of HPMA
copolymer-ALN-TNP-470 conjugate are expressed as mean6-
standard error of the mean (s.e.m.). Statistical significance was
determined using an unpaired t-test. P,0.05 was considered
statistically significant. All statistical tests were two-sided.
Results
Combination treatment of ALN and TNP-470 has
synergistic inhibitory effect on proliferation of
endothelial cells in vitro
Prior to conjugation of ALN and TNP-470 to HPMA
copolymer backbone, we evaluated the nature of the inhibitory
effect of the combination of ALN and TNP-470 on the
proliferation of endothelial cells in vitro. HUVEC were exposed
to free or combined ALN and TNP-470 (Figure 1A). Combination
treatments of ALN and TNP-470 decreased the IC of the drugs as
single treatments. ALN inhibited cell proliferation at inhibitory
concentrations with IC30, 50, 70 of 10, 50, 90 mM, and TNP-470
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Combination treatments I (serial concentrations of ALN and
TNP-470 at 0.01 pM) and combination treatments II (serial
concentrations of TNP-470 and ALN at 10 mM) inhibited
HUVEC proliferation at IC30, 50, 70 of 0.2, 10, 30 mM and
0.00001, 0.004, 40 nM respectively. Combination index-isobolo-
gram equation allowed quantitative determination of drug
interactions, where combination index ,1, =1, or .1 indicated
synergism, additive effect, or antagonism, respectively. Next, data
from combination treatments was calculated according to
combination index equation and was used to generate isobolo-
grams at IC30, 50, 70 of HUVEC proliferation by ALN-TNP-470
combinations (Figure 1B). Combination treatment I had synergis-
tic inhibitory effect on HUVEC at IC30, 50, 70 with combination
index of 0.055, 0.3, 0.89. Combination treatment II had
synergistic effect at IC 50, 70 with combination index of 0.23,
0.121 and additive effect at IC 30 with combination index of 1.025.
Synthesis and characterization of HPMA copolymer-ALN-
TNP-470 conjugate
HPMA copolymer-Gly-Gly-Pro-Nle-ALN-TNP-470 conjugate
was synthesized in two steps. First, an intermediate was
synthesized by copolymerization of HPMA, ALN monomer
(MA-Gly-Gly-Pro-Nle-ALN), and amino group containing mono-
mer (MA-Gly-Gly-Pro-Nle-NH(CH2)2NH2). Optionally, for the
evaluation of subcellular trafficking, a polymerizable derivative of
FITC, N-methacryloylaminopropyl (MA-FITC), was added to the
monomer mixture. In the second step, TNP-470 was linked to
amino groups by nucleophilic substitution of the terminal chlorine
of TNP-470 (Scheme S1).
The molecular weight and polydispersity of conjugates were
estimated by SEC exhibiting an apparent Mw of 80 kDa (Figure 2A
and 2B). Additionally, the hydrodynamic diameter size distribu-
tion of the HPMA copolymer-ALN-TNP-470 conjugates was
determined using an optical analyzer. The conjugate polymerized
by the classical polymerization method had a PDI of ,1.62 with a
mean size distribution of 241 nm whereas the conjugate
polymerized by ‘‘living polymerization’’ RAFT was well-dispersed
exhibiting a considerably lower and narrower PDI of ,1.2 with a
mean size distribution of 100 nm (Figure 2C). The values of mean
size distribution of the first conjugates, synthesized by the classical
polymerization method, clearly indicate that associates formed
under the experimental conditions used.
One of the main characteristics of ALN beside its anti-
angiogenic and antitumor activities is its pharmacokinetic profile,
which exhibits a strong affinity to bone mineral under physiolog-
ical conditions. To determine if the activity of ALN was retained
following polymer-conjugation, we evaluated the affinity of the
conjugate to bone mineral by in vitro HA binding assay. Following
2 min of incubation, 50% of the conjugate in the solution was
bound to HA. This rapid binding rate to HA was decreased after
10 min and finally reached a plateau after 175 min of incubation
time with 92% of bound conjugate (Figure 2D).
Intracellular trafficking of FITC-labeled HPMA copolymer-
ALN-TNP-470 conjugate in endothelial and Saos-2
human osteosarcoma cells
Following chemical characterization, we evaluated the ability of
FITC-labeled HPMA copolymer-ALN-TNP-470 conjugate to
internalize into endothelial and human osteosarcoma cells and
the mechanism by which it enters the cells. HUVEC and Saos-2
osteosarcoma cells were incubated with the conjugate, fixed,
permeabilzed and their nuclei were stained with PI. Confocal
microscopy performed by multi-channel tracking for PI (red) and
FITC-labeled conjugate (green). Following 12 h incubation,
conjugate accumulated mostly in the cytoplasm of HUVEC and
of Saos-2 cells as observed in the single plane image (Figure 3A).
To evaluate the conjugate cellular localization and to eliminate
optical artifacts, Z-stack of 5.7 mm with 28 slices (Figure 3B) and
X, Z slice (Figure 3C) were captured and analyzed. The conjugate
was found to be located at the same focal plane as the nuclei,
confirming its intracellular uptake. Further examination of the
conjugate cellular internalization was preformed using phalloidin
Figure 1. Combination treatment of ALN and TNP-470 has
synergistic inhibitory effect on proliferation of endothelial
cells in vitro. (A) ALN (closed squares) and TNP-470 (open squares)
had synergistic effect on HUVEC proliferation when combined as
ALN+TNP-470 0.01 pM (closed triangles) and TNP-470+ALN 10 mM
(open triangles). (B) Classic isobologram of ALN2TNP-470 combina-
tion treatment. IC70 (closed squares), IC50 (closed triangles) and IC30
(closed circles) of ALN and TNP-470. Dashed circles, represent
synergism areas of combination. Tables represent the combination
index values of each IC of combination treatments I and II. Drug
concentration in nM is presented on a logarithmic scale. Data represent
mean6s.d.
doi:10.1371/journal.pone.0005233.g001
Targeted Anticancer Therapy
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5233(red) for actin filaments and DAPI for nuclei staining. The staining
revealed accumulation of the conjugate mainly around the nuclei
in HUVEC (Figure 3D–G) and Saos-2 cells (Figure 3H–K). The
conjugate was capable of internalizing into HUVEC and Saos-2
cells as demonstrated by colocalization of 82% of the conjugate
with transferrin in HUVEC cells (Figure 3L–O) and of 71% in
Saos-2 cells (Figure 3P–S). These high percentages of colocaliza-
tion suggest a lysosomotropic pathway of cellular uptake via
clathrin-coated vesicles.
HPMA copolymer-ALN-TNP-470 conjugate inhibits the
proliferation of endothelial, Saos-2 and MG-63-Ras
human osteosarcoma cells
Next, we tested the inhibitory effect of HPMA copolymer-ALN-
TNP-470 conjugate on HUVEC, Saos-2 and MG-63-Ras human
osteosarcoma cell proliferation in order to determine whether it is
active in vitro and the bound drugs retained their antitumor and
anti-angiogenic activity following polymer-conjugation. ECGS-
induced proliferation of HUVEC was inhibited similarly by ALN-
TNP-470 combination and HPMA copolymer-ALN-TNP-470
conjugate at equivalent concentrations. The free and bound ALN
and TNP-470 exhibited an IC50 of 0.7 and 1 nM, and had
cytotoxic effect at doses higher than 1 and 10 nM respectively
(Figure 4). Saos-2 human osteosarcoma cell proliferation was
inhibited similarly by free and conjugated ALN-TNP-470 at IC50
of 30 mM (Figure 4, A). MG-63-Ras human osteosarcoma cell
proliferation was inhibited similarly by free and conjugated ALN-
TNP-470 at IC50 of 10 mM (Figure 4). HPMA copolymer alone
was inert in vitro and in vivo (data not shown) in agreement with
previously published data [57].
Figure 2. Characterization of HPMA copolymer-Gly-Gly-Pro-Nle-ALN-TNP-470 conjugates. SEC profiles of polymerization I (classical)
compound (A) and polymerization II (RAFT) compound (B). Hydrodynamic diameter size distribution (C) of polymerization I compound (gray bars)
and polymerization II compound (white bars). (D) Binding kinetics of HPMA copolymer-ALN-TNP-470 conjugate to HA.
doi:10.1371/journal.pone.0005233.g002
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osteosarcoma cells by confocal microscopy. (A) Single XY plane imaging of the conjugate (green) with PI (red) nuclei staining showed
cytoplasmatic accumulation of the conjugate. Cellular uptake analysis of the conjugate by HUVEC cells (B) 5.7 mm Z-stack of 28 slices and (C)X Z
image slice revealed similar conjugate and nuclei focal plane localization. Multi-channel overlay of (G) HUVEC and (K) Saos-2 cells stained with
phalloidin (red) for actin filaments (D, H) and DAPI (blue) for nuclei (F, J) 12 h post incubation with the conjugate (green)( E, I) showed cellular
localization of the conjugate mostly around the nuclei. The FITC-labeled conjugate (green) (L, P) colocalized with clathrin-coated vesicles labeled with
transferrin (red)( M, Q) in HUVEC (M, N) and Saos-2 (Q, R) cells. Histograms of overlay images revealed a ratio of conjugate/transferrin of 82% in
HUVEC (O) and 71% in Saos-2 (S) cells pointing at the cellular uptake of the conjugate via the lysosomotropic pathway. Scale bars represent (A–K)
5 mm and (L–S)2 0mm.
doi:10.1371/journal.pone.0005233.g003
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conjugate is active mainly upon the release of ALN and TNP-470
by cathepsin K cleavage mechanism, and not by spontaneous
hydrolysis, we evaluated the inhibition of HUVEC proliferation by
HPMA copolymer-ALN-TNP-470 conjugate in the presence of
cathepsin K inhibitor III (Figure 4). HPMA copolymer-ALN-
TNP-470 conjugate inhibited the proliferation of HUVEC at a 4-
logs higher concentration in the presence of cathepsin K inhibitor
III than in its absence. Following 72 h, there was probably some
free ALN and TNP-470 released hydrolytically from HPMA
copolymer-ALN-TNP-470 conjugate which led to the inhibition of
proliferation of HUVEC at concentrations higher than 4 mM
ALN-equivalent concentrations (Figure 4).
HPMA copolymer-ALN-TNP-470 conjugate inhibits
endothelial cells migration towards VEGF
We next examined the effect of HPMA copolymer-ALN-TNP-
470 conjugate on VEGF-induced HUVEC migration. Migration
was assessed by counting the number of cells that migrated
through the membranes towards the chemoattractant VEGF
during a 4 h period following 4 h treatment with free or
conjugated ALN-TNP-470. Treatments with free or conjugated
ALN-TNP-470 at equivalent concentrations of 0.1, 1, 10 nM
dramatically inhibited the chemotactic migration response to
VEGF compared with control (untreated) by 23% (P=0.038),
41% (P=0.003), 58% (P=0.013), and 18% (P=0.037), 35%
(P=0.032), 61% (P=0.006) respectively. HUVEC basal migration
in the absence of VEGF was 33% compared to VEGF-induced
cells (Figure 5A).
HPMA copolymer-ALN-TNP-470 conjugate inhibits
capillary-like tube formation of HUVEC in vitro
Having shown that free and conjugated ALN-TNP-470 have
anti-angiogenic potential by inhibiting ECGS-induced HUVEC
proliferation and migration towards the chemoattractant VEGF,
the ability to inhibit capillary-like tube formation of HUVEC was
tested. Free and conjugated ALN-TNP-470 at equivalent
concentrations of 0.01, 0.1, 1 nM inhibited capillary-like tube
Figure 4. Inhibition of proliferation of endothelial, Saos-2 and MG-63-Ras osteosarcoma cells by HPMA copolymer-ALN-TNP-470
conjugate. Free (open squares/triangles/diamonds) and polymer-conjugated ALN and TNP-470 (closed squares/triangles/diamonds) had
similar effect on cell proliferation exhibiting retention of activity following polymer conjugation. Free and conjugated ALN and TNP-470 inhibited
ECGS-induced HUVEC proliferation at IC50 of 0.7 and 1 nM respectively. Free and conjugated drugs had cytotoxic effect on these cells at doses .1
and 10 nM respectively. The inhibition of endothelial proliferation by the conjugate was reduced significantly (IC50=4200 nM) in the presence of
cathepsin K inhibitor III (open circles). Proliferation of Saos-2 and MG-63-Ras cells was inhibited by free and conjugated ALN and TNP-470 at higher
concentrations with IC50 of 30 mM and 10 mM respectively. The solid line represents the proliferation of growth factor-induced cells and the dotted
line represents the cell proliferation in the absence of ECGS. Data represent mean6s.d. * P,0.05, ** P,0.03, *** P,0.05 compared with control.
doi:10.1371/journal.pone.0005233.g004
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PLoS ONE | www.plosone.org 9 April 2009 | Volume 4 | Issue 4 | e5233Figure 5. Inhibition of VEGF-induced migration and capillary-like tube formation by HPMA copolymer-ALN-TNP-470 conjugate.
Free (dotted bars) and polymer-conjugated ALN and TNP-470 (gray bars) inhibited both (A) VEGF-induced HUVEC migration; and (B, C) capillary-like
tube formation of HUVEC, in a dose-dependent manner. Scale bars represent 100 mm. Drug concentration in nM is presented on a logarithmic scale.
All P values are two-sided (analysis of variance). Data represent mean6s.d. * P,0.05, ** P,0.03, *** P,0.05 compared with control.
doi:10.1371/journal.pone.0005233.g005
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(P=0.007), 73% (P=0.004), and 29% (P=0.021), 54%
(P=0.008), 64% (P=0.014) respectively (Figure 5B and 5C).
In vivo characterization of HPMA copolymer-ALN-TNP-
470 conjugate
Both conjugates synthesized by classical and by RAFT
polymerization reactions exhibited similar effects on the in vitro
assays described above. Therefore, we chose the narrowly
dispersed- and smaller in diameter RAFT-polymerized conjugate
for all in vivo studies due to an expected improved biodistribution.
HPMA copolymer-ALN-TNP-470 conjugate reduces
vascular hyperpermeability
We previously reported that TNP-470 and its conjugated form,
caplostatin, reduces VEGF-induced vascular hyperpermeability
[14], a prominent early feature of pathological angiogenesis. To
determine whether HPMA copolymer-ALN-TNP-470 conjugate
is able to reduce microvessel hyperpermeability we used a
modified Miles assay. Evans blue dye was injected to the retro-
orbital plexus and immediately thereafter the vascular permeabil-
ity-induced factor VEGF [58] was injected into the shaved flank of
Balb/c mice. Evans blue binds to plasma proteins and therefore
extravasates along with them at sites of increased permeability
[55]. VEGF-induced extravasation of Evans blue dye was
remarkably inhibited in mice treated with free combination of
ALN and TNP-470 and with HPMA copolymer-ALN-TNP-470
conjugate compared to vehicle treated mice by 87% (P=0.002)
and 92% (P=0.001), respectively (Figure 6A and 6B).
HPMA copolymer-ALN-TNP-470 conjugate inhibits MG-
63-Ras human osteosarcoma
SCID male mice bearing s.c. mCherry-labeled MG-63-Ras
human osteosarcoma showed decreased tumor growth rates when
treated with free and conjugated ALN and TNP-470 (1:1, 30 mg/
kg q.o.d. 3 times). The superiority of administering both drugs
when conjugated to the polymer compared to a cocktail of both
free drugs becomes evident when injected in vivo (Figure 6D).
HPMA copolymer-ALN-TNP-470 conjugate exhibited superior
antitumor activity compared to free ALN and TNP-470
combination treatment. On day 19 when control mice were
euthanized, HPMA copolymer-ALN-TNP-470 conjugate inhibit-
ed tumor growth by 96% (P=0.001) compared with 45%
(P=0.012) of free ALN and TNP-470 (n=5 mice per group;
Figure 6C and 6D). Confocal microscopy analysis of mCherry-
labeled tumors dissected from mice treated with FITC-labeled
HPMA copolymer-ALN-TNP-470 conjugate revealed high accu-
mulation of the conjugate at the tumor site (Figure 6E).
H & E staining of tumor sections of MG-63-Ras human
osteosarcoma tumors treated with combination of free TNP-470
and ALN or with the conjugate revealed that tumor sections from
control mice consisted of poorly differentiated tumor cells invasive
through the muscle layer with central calcified areas allowing the
HA-targeting of the conjugate with ALN. Conjugate-treated
tumors were almost regressed showing cholesterol deposits with
connective tissue and giant cells and macrophages around them as
signs of regression (Figure 6F). CD34 staining showed reduction of
39% (P=5.5610
211) in microvessel density (MVD) of combina-
tion of free ALN with TNP-470 (76614 microvessels/mm
2) and
74% (P=4.7610
219) reduction in MVD of conjugate-treated
tumors (3269 microvessels/mm
2) vs. control group of mice
(125616 microvessels/mm
2) (n=5 mice per group; Figure 6F).
Fluorescence imaging of organs dissected from mice treated
with FITC-labeled HPMA copolymer-ALN-TNP-470 conjugate
showed greater intensity of FITC-fluorescence spectrum (com-
posed images of unmixed multispectral cubes) in bone tissues then
in the spleen, heart, lungs, kidneys and liver (Figure 6G). Some
fluorescence is shown in the kidneys due to renal excretion of the
conjugate.
Discussion
This study describes a new concept of a combination therapy
that aims to target angiogenesis-dependent calcified neoplasms.
We achieved the synthesis of a conjugate with a predetermined
molecular weight with a narrow polydispersity and a high loading
of ALN using the RAFT polymerization technique. HPMA
copolymer-ALN-TNP-470 conjugate potentially delivers the anti-
angiogenic agent by dual targeting of angiogenesis-dependent
calcified tumors. ALN actively targets the conjugate to calcified
neoplasms whereas size-related passive accumulation is achieved
due to the enhanced permeability and retention effect (EPR)
typical to tumor blood vessels pathophysiology [19].
We have demonstrated that ALN acts as an anti-angiogenic
agent on its own and exhibits enhanced activity while combined
with TNP-470 due to their synergistic inhibitory effect on the
proliferation of endothelial cells. Furthermore, our nano-conjugate
is capable to internalize into the cytoplasm of HUVEC and Saos-2
human osteosarcoma cells via endocytosis. The conjugate
inhibited HUVEC proliferation, migration and capillary-like tube
formation in vitro. In addition, we showed that Saos-2 and MG-63-
Ras human osteosarcoma cell proliferation was similarly inhibited
by the conjugate and by the combined free drugs demonstrating
that the bound drugs retained their antitumor activity following
polymer conjugation. As a result, the in vivo antitumor efficacy of
TNP-470 and ALN have been substantially improved.
A different class of drug-delivery systems bearing a bone
targeting moiety has been reported by Hruby ´ et al., consisting of
HPMA copolymer-doxorubicin-hydroxybisphosphonate conjugate
bearing a cathepsin B-sensitive linker [59]. The conjugate was
tested in vitro showing HA binding and drug release. Wang et al.
described fluorescein-labeled bone-targeted model conjugates for
detection purposes bearing 1% loading of ALN or alternatively
Asp8 on HPMA copolymer [60]. The bone-targeting potential of
these conjugates was tested in vitro and in vivo and was found to
selectively accumulate in bone tissue. Here we describe a different
polymer conjugation technique, conjugating the ALN to the
monomer prior to copolymerization, thus controlling the drug
loading and enabling higher loading percentage of ALN (7% mol)
on the polymeric backbone. High loading of ALN offers both
rapid accumulation in bone tumors and metastases (which
produce calcified matter) and enhanced antitumor and anti-
angiogenic activity.
Combination therapy is routinely used in conventional
chemotherapy [61,62]. The advantages of polymer therapeutics
containing drug combinations have been previously demonstrated
[63,64,65]. The concomitant delivery of two agents that act
synergistically allow the administration of lower concentrations of
each drug increasing their combined antitumor efficacy and
decreasing their toxicity. However, these examples consisted of the
combination of two separate polymer-drug conjugates. Two
strategies of combined therapies based on a single polymeric
carrier with two drug combinations have been described [59,66].
The first polymer therapeutic to combine chemotherapy and
endocrine therapy was the HPMA copolymer conjugate carrying
both the aromatase inhibitor aminoglutethimide (AGM) and
Targeted Anticancer Therapy
PLoS ONE | www.plosone.org 11 April 2009 | Volume 4 | Issue 4 | e5233Targeted Anticancer Therapy
PLoS ONE | www.plosone.org 12 April 2009 | Volume 4 | Issue 4 | e5233doxorubicin for breast cancer therapy [66,67]. HPMA copoly-
mer–AGM–doxorubicin showed greater cytotoxicity towards
breast cancer cells in vitro than either of the individual conjugates,
or a simple mixture of them. The second combined conjugate
synthesized by Hruby ´ et al. was mentioned above. Given that
acquired drug resistance is a particular problem for many of the
new molecular targets, this new concept provides an interesting
opportunity for delivery of two drugs that might act synergistically
to block multiple cellular pathways simultaneously. Both combined
polymer therapeutics used doxorubicin as the cytotoxic drug and
cathepsin B-cleavable linkers. Here, we are targeting the
endothelial compartment and the bone tissue bearing the tumor.
We have used a cathepsin K-degradable linker, therefore
enhancing the specific active targeting to bone cancers.
Combined administration of angiogenesis inhibitors with
chemotherapies yield maximal benefits because such combinations
destroy two separate compartments of the tumor. Some anti-
angiogenic agents can ‘‘normalize’’ the abnormal tumor vascula-
ture, resulting in more efficient delivery of drugs and oxygen to the
targeted cancer cells, and enhancement of the efficacy of radiation
therapy and chemotherapeutic agents [68]. All of these mecha-
nisms imply that an anti-angiogenic agent would further augment
the response to chemotherapy. Despite the relatively good
tolerance of angiogenesis inhibitors when administered as single
agents, the non-targeted anti-angiogenic drugs often exhibit a non-
specific body distribution. This could result in different side effects
such as hypertension [69], proteinuria, bleeding, gastrointestinal
perforation, arterial thrombotic events [70], exfoliative dermatitis
[71] and skin toxicity [72]. Therefore, utilization of combination
therapy advantages with targeted drug delivery system is desirable
and was taken in consideration when we designed the described
conjugate.
The potent angiogenesis inhibitor TNP-470 has been conjugat-
ed previously to HPMA copolymer backbone through a Gly-Phe-
Leu-Gly-ethylenediamine, a cathepsin B-sensitive linker. Caplos-
tatin exhibited improved accumulation in tumor vasculature due
to passive targeting and had reduced toxicity compared to TNP-
470. As a result, caplostatin potently inhibited tumor angiogenesis,
vascular hyperpermeability and subsequent tumor growth
[13,14,16,22]. Our rationale in this study was to synthesize a
new polymeric drug delivery system combined of TNP-470 and a
strong bone seeking agent such as ALN, to achieve both synergistic
inhibitory antitumor effect and dual passive and active targeting
effect that could result in a rapid accumulation in bone-associated
neoplasms. It was previously shown that subcutaneous adminis-
tration of TNP-470 and HPMA copolymer-TNP-470 (caplostatin)
were effective [13,14]. Other possible routes of administration of
the conjugate are intravenous and intraperitoneal. Most likely,
intravenous administration will be the most effective because the
conjugate is directly administered into the blood circulation,
making the tumor endothelial cells, i.e. the conjugate’s target,
directly exposed to it.
Polymer-based nanocarriers similar to HPMA copolymer often
exhibit inherent structural heterogeneity of the polymers, reflected
in a high PDI. Homogenous size distribution of polymer
conjugates may contribute to a more defined biodistribution.
Here we demonstrate, for the first time, that we have a narrowly
dispersed combined antiangiogenic conjugate synthesized by
RAFT polymerization. Together with the cathepsin-K-cleavable
system we aim to achieve a more specific drug release and
therefore focus the toxicity of the free drugs to the bone tumor
sites.
It has been shown that ALN inhibits cell survival stimulated by
the PI3K/Akt/NFkB pathway via inhibition of the initial step, the
activation of PI3K, thus causing apoptosis of osteosarcoma cells
[73]. It also inhibits MMP-2 secretion by osteosarcoma cell lines
[48]. The synergistic effect of the combination of ALN and TNP-
470 might be the consequence of the different mechanisms of
action of the drugs.
HPMA copolymer-ALN-TNP-470 substantially inhibited oste-
osarcoma growth by 96%, whereas combined free drugs
demonstrated only 45% inhibition of tumor growth. Immunohis-
tochemical studies showed that HPMA copolymer-ALN-TNP-470
induced reduction of proliferation, invasiveness and angiogenesis.
H & E staining indicated a high level of tumor necrosis and signs
of regression following treatment. These results suggest that the
conjugate is bi-specific by preventing angiogenesis and causing
tumor cell death. Mori et al. showed that TNP-470 suppressed the
pulmonary metastasis of murine osteosarcomas [6]. There is
clinical pathological data showing that osteosarcomas preferen-
tially metastasize to the lungs and that these lesions frequently
produce calcified bony tissue where osteoid and bone spicules are
abundant [74], thus the ALN-bound conjugate could potentially
target these metastases as well. Furthermore, the conjugate will
target tumors in any site where the vessels are hyperpermeable.
Our nanoconjugate will extravasate from those leaky vessels and
accumulate in the tumor due to the EPR effect.
The expected advantages of our targeted nano-conjugated
polymer therapeutic over the free drugs are (1) longer circulation
time due to increased half-life of the drug following polymer
conjugation; (2) increased accumulation in tumors compared to
normal healthy tissues due to the EPR effect [75]; (3) binding of
several BP groups per chain provides a stronger bond to HA
delivering higher amounts of TNP-470 or any other drug to the
tumor site; (4) elimination of blood brain barrier crossing thus
abrogating neurotoxicity; (5) improved antitumor effect due to the
fact that TNP-470 and ALN act synergistically as anticancer and
anti-angiogenic combination therapy; and (6) solubilization of an
insoluble drug. All these advantages led to a significant increase in
therapeutic efficacy in an animal model that is highly clinically
Figure 6. HPMA copolymer-ALN-TNP-470 conjugate reduces vascular hyperpermeability in mouse skin capillaries and inhibits MG-
63-Ras human osteosarcoma growth. (A) Diminished dye is observed in mice treated with free or conjugated ALN and TNP-470 compared to
untreated control group. Scale bar represents 10 mm. (B) Extracted dye content quantification by measurement at 620 nm. (C) Intravital non-invasive
fluorescence imaging of mCherry-labeled MG-63-Ras tumor-bearing mice treated with free or conjugated ALN and TNP-470. (D) Antitumor effect of
free (open triangles) or conjugated (closed triangles) ALN and TNP-470 on MG-63-Ras human osteosarcoma tumor growth compared to vehicle-
treated group (closed squares) and dissected tumors images. Scale bar represents 10 mm. All P values are two-sided. On day 19 HPMA copolymer-
ALN-TNP-470 conjugate inhibited tumor growth by 96% (P=0.001) compared with 45% (P=0.012) of free ALN and TNP-470. Data represent
mean6s.d. * P,0.05, ** P,0.03, *** P,0.05 compared with control. (E) Whole-mount confocal microscopy of mCherry-labeled MG-63-Ras human
osteosarcoma tumors dissected from mice treated with FITC-labeled HPMA copolymer-ALN-TNP-470 conjugate. Scale bar represents 25 mm( n=5
mice per group). (F) H & E and CD34 staining of control, combination- and conjugate-treated MG-63-Ras osteosarcomas inoculated s.c. in mice. (G)
Dissected organs of mice treated with FITC-labeled HPMA copolymer-ALN-TNP-470 conjugate were imaged by the Maestro system showing greater
intensity of FITC-fluorescence spectrum (composed images of unmixed multispectral cubes) in bone tissues then in the spleen, heart, lungs, kidneys
and liver. Green represent FITC-labeled HPMA copolymer-ALN-TNP-470 conjugate spectrum.
doi:10.1371/journal.pone.0005233.g006
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PLoS ONE | www.plosone.org 13 April 2009 | Volume 4 | Issue 4 | e5233relevant. This approach warrants the clinical translation of the
therapeutic platform described here to be used for calcified
neoplasms, bone metastases and other angiogenesis-dependent
diseases.
Supporting Information
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